QLM 3003
Alternative Names: QLM-3003Latest Information Update: 04 Oct 2023
At a glance
- Originator Qilu Pharmaceutical
- Class Anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Atopic dermatitis
Most Recent Events
- 28 Sep 2023 Qilu Pharmaceutical plans a phase II trial for Atopic dermatitis in China (NCT06058000)
- 30 Aug 2023 Qilu Pharmaceutical completes a phase I trial in Atopic dermatitis (In volunteers, In adults) in China (unspecified route) (NCT05932888)
- 12 Jul 2023 QLM 3003 is available for licensing as of 12 Jul 2023. https://en.qilu-pharma.com/development/2.html (Qilu Pharmaceutical website, July 2023)